Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), and connected persons in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
On October 9, 2014, several GSK Directors and PDMRs acquired Ordinary Shares through the GSK ShareReward Plan. The transaction details are as follows:
- Share Price: 1400.26 pence per Ordinary Share.
- Participants: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Transaction Volume: Each of the nine Directors/PDMRs acquired 9 shares under the personal contribution element and 9 shares under the matching element (GSK contribution).
- Connected Person: Mrs K Thomson (connected to Mr P C Thomson) acquired 1 share under the personal contribution element and 1 share under the matching element.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share acquisitions listed above.
Investor Verification Checklist
- Verify the total number of shares acquired by each Director and PDMR under the ShareReward Plan.
- Confirm the share price of 1400.26 pence per Ordinary Share as of October 9, 2014.
- Review the full text of the GSK ShareReward Plan to understand the matching contribution rules.
- Check subsequent filings for any additional director transactions or financial results for the period.